Ampio Pharma rises after dosing begins in COVID-19 drug study

Ampio Pharmaceuticals

25/06/2021 15:00

** Drug developer's shares  AMPE.A  rise 1.6% to $1.81
    ** Co says dosing of patients is underway in a mid-stage
study testing inhaled version of lead drug candidate, Ampion, in
treatment of respiratory distress due to COVID-19 (https://refini.tv/3zXeGWJ)
    ** Ampio also recently received approval from the U.S. FDA
to expand the study to India  urn:newsml:reuters.com:*:nL3N2NX2RC
    ** Stock up about 14% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com))